Rankings
▼
Calendar
RAPP Q3 2024 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
RAPP
Rapport Therapeutics, Inc. Common Stock
$1B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$22M
Net Income
-$18M
EPS (Diluted)
$-0.09
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$16M
Free Cash Flow
-$17M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$331M
Total Liabilities
$8M
Stockholders' Equity
$323M
Cash & Equivalents
$39M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$22M
-$10M
-126.3%
Net Income
-$18M
-$9M
-101.4%
← FY 2024
All Quarters
Q4 2024 →